Liver Disease Clinical Trials 2022

Browse 64 Liver Disease Medical Studies Across 132 Cities

3 Phase 3 Trial · 376 Liver Disease Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

SHAPE Measurement (Sonazoid Ultrasoud Contrast Agent)for Liver Diseases

Philadelphia, PA
18+
All Sexes
This is an open-label, non-randomized trial that will be conducted at three clinical sites, Thomas Jefferson University (TJU), the Hospital of the University of Pennsylvania (HUP) and University of Bern (UB). Enrollment will be allocated into one of 4 different cohorts depending on the inclusion criteria for each cohort. Cohort 1: Patients scheduled for hepatic vein pressure gradient (HVPG) measurements will subsequently undergo two consecutive SHAPE (subharmonic aided pressure estimation) procedures using different ultrasound contrast agents (Definity [Lantheus Medical Imaging, N Bilerica, MA, USA] and Sonazoid [GE Healthcare, Oslo, Norway] in randomized order) to estimate portal pressures with a Logiq E10 scanner (GE Healthcare, Waukesha, WI, USA) and determine the reproducibility of the SHAPE algorithm. Cohort 2: Patients identified as having clinically significant portal hypertension (CSPH) will be monitored by SHAPE with Sonazoid for the duration of this project (18-24 months on average). These subjects will have follow-up ultrasound scans every 6 ± 2 months to check for hepatocellular carcinoma (HCC) (using the Barcelona-Liver Cancer staging system) as well as ascites and at those times a repeat SHAPE examination will be performed. Liver stiffness values will be measured with elastography as well. This cohort will examine if serial SHAPE can accurately predict development of ascites and other liver related events in patients with compensated cirrhosis undergoing routine HCC surveillance in a multi-center setting. Cohort 3: Subjects newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE and results compared to elastography measurements of liver stiffness with standard assessments (e.g., serum liver function tests and measurement of spleen size as well as platelet count). This cohort will establish if SHAPE can be used to monitor treatment response in patients identified with portal hypertension. Cohort 4: Patients with compensated advanced chronic liver disease scheduled for an endoscopy examination for screening of varices relative to the Baveno VI and the expanded-Baveno VI criteria as well as the AST to Platelet Ratio Index will undergo a SHAPE examination. This cohort will compare the predictive ability of SHAPE for allocating patients with compensated advanced chronic liver disease to screening of varices compared to the current standard of care.
Phase 3
Waitlist Available
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

BI 456906for Obesity

San Antonio, TX
18+
All Sexes
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body. The purpose of Part 2 is to find out whether having liver problems influences how people with overweight and obesity tolerate different doses of BI 456906. In Part 1, participants get a single injection of BI 456906 under their skin and stay at the study site for 2 nights afterwards. They are in the study for about a month. During this time, they visit the study site about 8 more times. The doctors compare the amount of BI 456906 in the blood of healthy people and people with liver problems. In Part 2, participants get 1 or 2 injections of BI 456906 once a week under their skin for 28 weeks. At the beginning, they get lower doses of BI 456906. Over time, they get higher doses until they reach a certain dose of BI 456906. This dose is then maintained until the end of the treatment. Participants in Part 2 are in the study for about 7 months. During this time, they visit the study site about 16 times and get about 15 phone calls from the site staff. The doctors record the number of people with health problems that could have been caused by treatment with BI 456906. They compare the results between participants with liver problems and those without liver problems. In both parts, doctors also regularly check participants' health and take note of any unwanted effects.
Phase 1
Recruiting
25 Liver Disease Clinical Trials Near Me
San Antonio, TX
Richmond, VA
Richmond, VA
Philadelphia, PA
More Trial Locations
An interactive map to display trial locations for Texas Liver Institute, Hunter Holmes McGuire VA Medical Center, Virginia Commonwealth University, Thomas Jefferson University, Dept of Radiology, and 74 more locations.
Most Popular References for Liver Disease Clinical Trials
Frequency
Citation
Top Hospitals for Liver Disease Clinical Trials
Location
Active Liver Disease Clinical Trials
All Time Trials for Liver Disease
First Recorded Liver Disease Trial
Trials
Massachusetts General Hospital, Boston, Massachusetts
4
20
2010
Top Treatments for Liver Disease Clinical Trials
Top Cities for Liver Disease Clinical Trials
City
Active Liver Disease Clinical Trials
Top Active Site for Liver Disease Clinical Trials
Trial List
Los Angeles, California
9
National Research Institute - Los Angeles
Phase 3 Liver Disease Clinical Trials
Senior Friendly Liver Disease Clinical Trials
Recently Completed Studies with FDA Approved Treatments for Liver Disease
Treatment
Year
Mechanism of Action
Sponsor
Active Liver Disease Clinical Trials
Nitazoxanide
2021
Nitazoxanide
Genfit
0
Soticlestat
2021
Takeda
0
Bocidelpar
2021
Astellas Pharma Global Development, Inc.
0
Sotorasib
2021
Sotorasib
Amgen
0
parsaclisib
2021
Parsaclisib
Incyte Corporation
0
MK-8189
2021
Merck Sharp & Dohme Corp.
0
PF-06882961 20MG
2020
PF-06882961
Pfizer
0
Ozanimod
2020
Ozanimod
Celgene
0
PF-06865571
2020
Pfizer
0
KD025
2019
Belumosudil
Kadmon Corporation, LLC
0

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 31st, 2021

Last Reviewed: August 16th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.